Research · Sep 3, 2026
[PHG] Philips Thesis 2026: Diagnostic Imaging Recovery Drives Post-Respironics Margin Expansion
Koninklijke Philips N.V. (NYSE: PHG) FY2025 revenue ~€18-19B (+0-5%) with adj. EPS ~€1.30-1.55 reflecting continued post-2024 Diagnosis & Treatment (~€10-11B; +3-5%) recovery + Connected Care (~€5-5.5B; +0-3%) + Personal Health (~€2.5-3B; +3-5%) plus selected post-September 2024 ~$1.1B aggregate Respironics CPAP recall litigation settlement (~Philips Personal Health respiratory care unit ~$1.1B aggregate Massachusetts federal court class action settlement covering ~$479M economic loss + ~$25M medical monitoring + ~$596M selected various claims) under continued President + CEO Roy Jakobs (~3-year tenure since October 2022). Global health technology company focused on Diagnosis & Treatment + Connected Care + Personal Health. Founded 1891 in Eindhoven Netherlands by Anton + Gerard Philips (~134-year heritage); selected post-1948 NYSE ADR listing + Royal Dutch designation; selected post-2007 ~$5.1B Spectramed; selected post-2014 ~$3.3B Volcano + Lighting business spin-off (Signify Lighting); selected post-2019 Healthcare strategic refocus; selected post-June 2021 Respironics CPAP voluntary recall; selected post-September 2024 ~$1.1B Massachusetts federal court class action settlement; selected post-October 2022 Roy Jakobs CEO appointment. Headquartered in Eindhoven Netherlands; ~70,000+ employees globally with ~€18-19B revenue. Three primary business segments: Diagnosis & Treatment (~55% revenue ~€10-11B), Connected Care (~25% ~€5-5.5B), Personal Health (~15% ~€2.5-3B). Diagnostic imaging cycle recovery: Diagnosis & Treatment ~€10-11B FY2025 (+3-5% YoY); CT + MR + X-ray + ultrasound + interventional + selected various; selected continued post-2024 hospital + health system capital expenditure cycle recovery; AI-enabled imaging integration. Respironics post-recall settlement progress: post-June 2021 voluntary recall ~5.5M Respironics CPAP devices; post-2021 ~$1.0B aggregate provisions; post-September 2024 ~$1.1B Massachusetts settlement (~$479M economic loss + ~$25M medical monitoring + ~$596M selected various); post-2024 ~3-4% North America Respironics CPAP market share rebuilding. Capital return: ~€0.85-0.90 annual dividend FY2025 (~+0-5% growth; ~30+ year continuous dividend track); ~€500M-1B FY2024-2025 buyback program; aggregate capital return ~€1.5-2B; net debt ~€8-10B; investment-grade Baa2/BBB credit rating. President + CEO Roy Jakobs since October 2022 (~3-year tenure); CFO Charlotte Hanneman. FY2026 thesis: Diagnostic imaging recovery + Respironics post-settlement progress + Connected Care + Personal Health continued growth + ~30+ year continuous dividend track + selected post-2024 capital deployment. Risks: hospital + health system capex cycle, Respironics post-settlement litigation + regulatory progression, GE HealthCare + Siemens Healthineers + Canon Medical competition, Personal Health cyclical, USD/EUR + USD/CNY currency volatility.